JUNE 02, 2022 (NewsRx) — By a News Reporter – Staff News Editor at Health policy and daily law — The results of the current psoriatic arthritis study have been released. According to reports from Boston, MA, by NewsRx editors, the research said, “Specialty drugs provide effective treatment with limited adverse effects for patients with psoriasis and psoriatic arthritis; however, variable coverage and high costs often create a barrier to treatment for patients with commercial health insurance.
Journalists got a citation from the research of Tufts Medical Center“Our objective was to assess the coverage of specialist drugs for psoriasis and psoriatic arthritis by commercial insurance companies. We compiled data regarding specialty drug coverage for psoriasis and psoriatic arthritis using the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) database and analyzed the data for any notable trends. The SPEC database lists coverage decisions for 158 specialty drugs by 17 of the largest US commercial health plans, along with data regarding the types of evidence these insurance plans cite when making coverage decisions. Our results showed that insurance plans tend to be more restrictive than American Food and Drug Association (FDA) to cover drugs for psoriasis and psoriatic arthritis. Additionally, drugs for psoriatic arthritis tended to be less restricted than for psoriasis, and drugs were most often approved as second-line agents for both indications.
According to the journalists, the research concluded: “Our analysis confirms that there is variability in insurance coverage for the indications of psoriasis and psoriatic arthritis.”
For more information on this research, see: Coverage of specialty drugs for psoriasis and psoriatic arthritis by commercial insurance companies. Journal of Psoriasis and Psoriatic Arthritis2022. The editor of Journal of Psoriasis and Psoriatic Arthritis is SAGE Publications.
A free version of this review article is available at https://doi.org/10.1177/24755303221101843.
Our editors report that additional information can be obtained by contacting Christina learned, Department of Dermatology, Tufts Medical Center, Boston, MA, United States. Other authors of this research include Sara Alsukait, Kristin R Fiumara, Melissa OrtegaJames D Chambers, David Rosmarin.
ORCID is an identifier for authors and includes bibliographic information. Here is the ORCID information for the author of this search: David Rosmarin (http://orcid.org/0000-0003-2786-0708).
(Our reports provide factual information on research and discoveries from around the world.)
